Remove Antibody Remove In-Vitro Remove Life Science Remove Reagent
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The antibodies are conjugated to fluorochromes for them to be detected. What is Flow Cytometry?

article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1.

article thumbnail

Highlights from SLAS2023: Day One

Drug Discovery World

“We’re transforming drug discovery, and it all begins in the lab where researchers can leverage multimode plate reader technology like the EnVision Nexus system to increase R&D productivity at nearly every stage of their process,” said PerkinElmer Senior Vice President of Life Sciences Alan Fletcher. “By

Drugs 52